Institutional members access full text with Ovid®

Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy

Curran, Adriana; Martinez, Estebanb; Saumoy, Mariac; del Rio, Luisd; Crespo, Manuela; Larrousse, Mariab; Podzamczer, Danielc; Burgos, Joaquina; Lonca, Montseb; Domingo, Peree; Gatell, Jose Mariab; Ribera, Estebana

doi: 10.1097/QAD.0b013e32834f3507
Clinical Science

Objective: To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r.

Design: Substudy of the prospective, randomized, open-label, multicenter SPIRAL study.

Methods: Patients were randomized (1 : 1) to continue with the PI/r-based regimen or switch to RAL, maintaining the rest of the treatment unchanged. Dual-energy X-ray absorptiometry and computed tomography scans were performed at baseline and after 48 weeks to measure body fat and bone composition, analyzing intragroup and intergroup differences.

Results: Eighty-six patients were included and 74 patients (39 RAL, 35 PI/r) completed the substudy. Significant increases in median [interquartile range (IQR)] visceral adipose tissue (VAT) [20.7 (−2.4 to 45.6) cm2, P = 0.002] and total adipose tissue (TAT) [21.4 (−1.3 to 55.4) cm2, P = 0.013] were seen within the PI/r group. No significant changes in body fat were seen with RAL or between treatment groups. Regarding bone composition, total BMD [0.01 (0 to 0.02) g/cm2, P = 0.002], total hip BMD [0.01 (0 to 0.03) g/cm2, P = 0.015] and total hip T score [0.12 (−0.05 to 0.21) SD, P = 0.004] significantly increased with RAL, with no significant changes within the PI/r group. Differences between treatment groups were significant in femoral neck BMD [0.01 (−0.02 to 0.02) g/cm2, P = 0.032] and T score [0.01 (−0.18 to 0.18) SD, P = 0.016].

Conclusion: Although there were no significant changes in body fat between groups, maintaining a PI/r-based regimen was associated with a significant increase in VAT and TAT. Switching to RAL led to a significant increase in femoral neck BMD when comparing between groups.

aHospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Infectious Diseases Department

bHospital Clinic i Provincial, Infectious Diseases Department

cHospital Universitari de Bellvitge, HIV Unit, Infectious Diseases Department, L’Hospitalet de Llobregat

dCETIR, Nuclear Medicine Department

eHospital Universitari Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Infectious Diseases Department, Barcelona, Spain.

Correspondence to Adrian Curran, MD, Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain. Tel: +34 93274 6090; fax: +34 9348 94091; e-mail: acurran@vhebron.net

Received 27 September, 2011

Revised 9 November, 2011

Accepted 14 November, 2011

© 2012 Lippincott Williams & Wilkins, Inc.